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Body mass index at the onset of hidradenitis 
suppurativa
Dear Editors,
Hidradenitis suppurativa (HS) has a well-known association 
with increased body mass index (BMI). However, studies on 
BMI in HS patients were performed after an average disease 
duration of 13.8–15.5 years [1–3]. It remains unclear to what 
extent increased BMI predisposes to development of HS. In-
creased BMI could potentially be a result of HS-related sym-
ptoms such as depression [4]. Therefore, the aim of this study 
was to retrospectively investigate the BMI of HS patients at 
the onset of the disease and to compare this to age-matched 
Dutch population data.
All consecutive HS patients attending the HS clinic of a 
tertiary center in the Netherlands between May and Septem-
ber 2017 were included. Patients retrospectively selected a 
silhouette from the Stunkard Figure Rating Scale correspon-
ding with their body size at the age of the first HS symptoms. 
These figures were converted into underweight and normal 
weight, overweight, or obesity according to previous publica-
tions [5, 6]. Patient characteristics were collected from medi-
cal records. General population data was collected through 
the open-access database (StatLine) of Statistics Netherlands 
[7]. Categorical BMI data in this database is available stra-
tified per age group (for example, 16–20 years) from 1981 
up to now, obtained through yearly questionnaires send to 
a random sample of the Dutch population. To create age-
matched groups, patients were categorized into the StatLine 
age groups according to the age of HS onset. The average 
year of onset within these groups was used for comparison 
with population data. Groups with < 15 patients were exclu-
ded from the analyses. Statistical analysis was performed 
using SPSS Statistics (IBM, version 24), with P-values ≤ 0.05 
considered significant. Under Dutch law this study is exempt 
from medical ethical committee approval.
At the time of inclusion 70.7 % of the 239 included pati-
ents were overweight/obese with a mean BMI of 28.98 ± 6.11 
(Table 1). Seven patients could not recall the age of onset and 
were excluded from analysis. At the age of HS onset 40.5 % 
of patients were overweight or obese. Groups with an age 
of onset under 16 years (n = 6), between 40–50 years (n = 
12) and between 50–65 years (n = 9) were excluded from 
the analysis. Patients with a disease onset between 12–16 ye-
ars, 16–20 years, and 20–30 years were significantly more 
often overweight/obese compared with their age-matched 
 Clinical Letter Table 1 Patient characteristics.
Included patients
n = 239
Female, n (%) 151 (63.2 %)
Age, mean ± SD 38.75 ± 12.83
 Age of onset, mean ± SD 22.84 ± 11.21
 Missing, n 7
Current BMI, mean ± SD 28.98 ± 6.11
 Under- or normal weight, n (%) 70 (29.3 %)
 Overweight, n (%) 72 (30.1 %)
 Obese, n (%) 97 (40.6 %)
FRS at onset
 1, n (%) 14 (5.9 %)
 2, n (%) 28 (11.7 %)
 3, n (%) 47 (19.7 %)
 4, n (%) 54 (22.6 %)
 5, n (%) 36 (15.1 %)
 6, n (%) 32 (13.4 %)
 7, n (%) 17 (7.1 %)
 8, n (%) 7 (2.9 %)
 9, n (%) 4 (1.7 %)
BMI at onset
 Under- or normal weight  
 (FRS 1–4), n (%)
138 (59.5 %)
 Overweight (FRS 5–7), n (%) 85 (36.6 %)
 Obese (FRS 8–9), n (%) 9 (3.9 %)
 Missing, n 7
Smoking status
 Current or ex-smoker, n (%) 189 (79.1 %)
 Non-smoker, n (%) 44 (18.4 %)
 Missing, n 6
Hurley stage
 Stage I, n (%) 81 (33.9 %)
 Stage II, n (%) 106 (44.4 %)
 Stage III, n (%) 52 (21.8 %)
Abbr.: BMI, body mass index; FRS, Stunkard Figure Rating 
Scale.
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peer group (respectively P < 0.001, P < 0.001, and P = 0.01) 
(Figure 1). The BMI did not significantly differ in patients 
with a disease onset between 30–39 years. No significant dif-
ferences in BMI at HS onset were found for sex, family his-
tory, or smoking status. No association was found between 
BMI at disease onset and current disease severity (Hurley 
stage).
This is the first study to assess BMI at the age of HS 
onset. The results of this study support a predisposing role 
of high BMI in the development of HS, at least in a sub-
group of HS patients. Potentially, obesity-induced low-grade 
inflammation could prime the skin of HS patients towards a 
pro-inflammatory state with other factors such as genetics, 
smoking or hormonal influences providing additional hits 
towards developing HS [8]. This raises the question whether 
the subclinical inflammation seen in uninvolved HS skin 
could be regarded as obesity related inflammation or whether 
it represents a disease specific pro-inflammatory milieu in the 
skin of HS patients. In addition, Vossen et al. demonstrated 
that HS patients have a more peripheral fat distribution com-
pared with controls which may result in increased friction 
between skin folds, potentially promoting HS-associated fol-
licular occlusion [9]. However, our results do not exclude an 
effect of HS itself on BMI after disease onset. Hidradenitis 
suppurativa associated symptoms such as pain, contractu-
res, and fatigue could reduce physical activity leading to an 
additional increase in BMI [10]. Moreover, the majority of 
patients had normal weight at disease onset and several stu-
dies have shown that certain HS phenotypes within the HS 
Figure 1 Categorical BMI at the onset of HS compared with the general population. Onset 12–16 years (a). Onset 16–20 years 
(b). Onset 20–30 years (c). Onset 30–40 years (d). HS, hidradenitis suppurativa. Categorical BMI data was analyzed using 
Fisher’s Exact tests.
population are associated with normal BMI [11]. Therefore, 
increased BMI may only serve as a predisposing factor in a 
subset of HS patients.
Our results may be subject to recall bias due to the re-
trospective nature of the study. Nonetheless, we would ex-
pect patients to choose a smaller body silhouette over a cur-
vier one, most likely leading to an underestimation of our 
results rather than an overestimation. The well-known dia-
gnostic delay poses great difficulties in assessing the causa-
lity between increased BMI and development of HS. Large, 
prospective, long-term follow-up studies of initially healthy 
participants would be required to provide evidence for a cau-
sal relationship between BMI and HS.
In conclusion, patients with an HS onset between 12 and 
30 years were more frequently overweight or obese at that 
age than the general population. These results suggest a pre-
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